Author: Larsson Per-Anders Glimelius Bengt Jeppsson Bengt Jönsson Per-Ebbe Malmberg Martin Gustavsson Bengt Carlsson Göran Svedberg Margit
Publisher: Informa Healthcare
ISSN: 0284-186X
Source: Acta Oncologica, Vol.39, Iss.1, 2000-04, pp. : 59-63
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
The present study was designed to study 5-FU pharmacokinetics after interferon. Weekly bolus 5-FU (500 mg/m2), immediately followed by leucovorin (60 mg/m2) was given in 14 weekly cycles to 55 gastrointestinal and breast cancer patients. Interferon-α was given on days 2, 4 and 6, starting from cycle 2 at a dose of 0.5 million units (MU) and stepwise increased to 12 MU in cycles 12 and 13. Five patients could not tolerate the treatment even at the lowest dose of interferon and 22 patients were unavailable for the pharmacokinetic analysis because of dose reductions of 5-FU. Five patients were able to follow the protocol to 12 MU, whereas most patients were unable to continue owing to toxicity. 5-FU pharmacokinetics was analysed every second cycle. Peak concentration and AUC were increased after 12 MU of interferon, but no other significant influence of interferon on pharmacokinetic parameters of 5-FU was observed.
Related content
By Hausmaninger H. Moser R. Samonigg H. Mlineritsch B. Schmidt H. Pecherstorfer M. Fridrik M. Kopf C. Nitsche D. Kaider A. Ludwig H.
European Journal of Cancer, Vol. 35, Iss. 3, 1999-03 ,pp. :
By Allen M. Vaughan M. Webb A. Johnston S. Savage P. Eisen T. Bates S. Morre J. Ahern R. Gore M.
Urologic Oncology: Seminars and Original Investigations, Vol. 7, Iss. 2, 2002-03 ,pp. :
By Constenla Manuel Garcia-Arroyo Ramon Lorenzo Isabel Carrete Nancy Campos Begoña Palacios Patricia
Gastric Cancer, Vol. 5, Iss. 3, 2002-09 ,pp. :